ZAGROS DAROU Competitors

Our people are our strength. And together with over 54,000 colleagues, we're creating the next breakthrough in the world of healthcare and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint

CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.

SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.